NAP125 Inhibitors belong to a specific category of chemical compounds designed to target and inhibit the activity of the NAP125 protein. NAP125, also known as Nucleosome Assembly Protein 125, is a critical factor involved in the assembly and organization of nucleosomes, which are the fundamental structural units of chromatin. Chromatin is a complex of DNA and proteins found in the cell nucleus, and it plays a central role in regulating gene expression and packaging DNA within the nucleus. Inhibitors of NAP125 are primarily developed for research purposes, serving as essential tools for molecular biologists and cell biologists to delve into the intricate mechanisms of chromatin organization, gene regulation, and nucleosome assembly.
NAP125 inhibitors are typically composed of small molecules or chemical compounds designed to interact with the NAP125 protein, thereby disrupting its normal function. By inhibiting NAP125, these compounds can potentially interfere with nucleosome assembly and chromatin organization processes, leading to alterations in gene expression and chromatin structure. Researchers utilize NAP125 inhibitors in laboratory settings to manipulate the nucleosome assembly pathways and investigate the role of NAP125 in these fundamental cellular processes. These inhibitors facilitate the exploration of the molecular intricacies of chromatin dynamics and nucleosome assembly, contributing to a deeper understanding of how genes are regulated and how DNA is packaged within the cell nucleus. While NAP125 inhibitors may have broader implications, their primary purpose is to aid scientists in deciphering the molecular mechanisms underlying chromatin organization and gene expression.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Interferes with eukaryotic protein synthesis, potentially reducing NCKAP1 protein levels by inhibiting translation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
A polyphenol that may modulate signal transduction, possibly affecting NCKAP1 expression indirectly. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that may lead to a reduction in protein synthesis rates, affecting NCKAP1 protein levels. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that could disrupt signaling pathways and indirectly decrease NCKAP1 expression. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Can crosslink DNA, potentially affecting the transcription of genes like NCKAP1. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
May influence various signaling pathways, with possible downstream effects on NCKAP1 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An MEK inhibitor that might alter ERK pathway signaling, potentially affecting NCKAP1 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that could modulate cellular stress responses, indirectly impacting NCKAP1 expression. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
May affect transcription factors and inhibit NF-κB activation, potentially reducing NCKAP1 expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which could influence signaling pathways affecting NCKAP1. | ||||||